Accordingly, in vivo treatment of the xenografts with BMS-345541 significantly inhibited TNF-induced NF-κB signaling activation in blastic cells (Supplementary Fig. 9b and Extended Data Fig. 9i) and reduced BM tumor burden (Fig. 3e). Here, NFKB1 is linked to neoplasm.